Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026
Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026
Company Deals

Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma

Fineline Cube Jul 27, 2023

Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...

Company

Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast

Fineline Cube Jul 27, 2023

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...

Company Deals

AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research

Fineline Cube Jul 27, 2023

AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...

Company

GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance

Fineline Cube Jul 27, 2023

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...

Company Drug

Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone

Fineline Cube Jul 27, 2023

Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...

Company Drug

Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA

Fineline Cube Jul 27, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...

Company Deals

Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology

Fineline Cube Jul 27, 2023

Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...

Company Drug

Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD

Fineline Cube Jul 27, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....

Company Deals

Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal

Fineline Cube Jul 27, 2023

Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...

Company Drug

SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome

Fineline Cube Jul 27, 2023

China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...

Company Drug

Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE

Fineline Cube Jul 26, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that the...

Company Medical Device

Sisram Medical’s Alma Veil Launches in the US for Vascular Lesion Treatment

Fineline Cube Jul 26, 2023

Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...

Company Drug

AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study

Fineline Cube Jul 26, 2023

The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...

Company Deals

Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline

Fineline Cube Jul 26, 2023

Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...

Company Drug

Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC

Fineline Cube Jul 26, 2023

Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...

Company Drug

HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study

Fineline Cube Jul 26, 2023

Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...

Company Deals

Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal

Fineline Cube Jul 26, 2023

Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...

Company Drug

InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study

Fineline Cube Jul 26, 2023

Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease

Fineline Cube Jul 26, 2023

Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...

Company

Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts

Fineline Cube Jul 26, 2023

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...

Posts pagination

1 … 499 500 501 … 668

Recent updates

  • Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
  • Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
  • Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
  • BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.